ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID treatment

Baricitinib improves survival rate and reduces the need for ventilation, guidelines say

An Eli Lilly pharmaceutical manufacturing plant in Branchburg, New Jersey. The French medical charity Medecins Sans Frontieres said baricitinib can be a potential alternative to scarce monoclonal antibody treatments.   © Reuters

A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly, and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more